Januvia<sup>®</sup>: sitagliptin for type 2 diabetes

  • Jacky van Schoor

Abstract

Januvia® is available as a film-coated tablet that contains 25 mg, 50 mg and 100 mg of sitagliptin-free base, respectively. As monotherapy, it is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus. It is also indicated to increase glycaemic control in patients with type 2 diabetes mellitus, in combination with metformin or a peroxisome proliferator-activated receptor gamma (PPARγ)-agonist, e.g. a thiazolidinedione, when diet and exercise, together with the single agent, do not provide adequate glycaemic control.1
Section
New Product Focus